Shopping Cart
- Remove All
- Your shopping cart is currently empty
Abd110 (compound 42i), a Lenalidomide-based PROTAC ATR kinase degrader, selectively reduces levels of ATR and phospho-ATR while not impacting the related kinases ATM and DNA-PKcs [1].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
10 mg | Inquiry | Inquiry | |
50 mg | Inquiry | Inquiry |
Description | Abd110 (compound 42i), a Lenalidomide-based PROTAC ATR kinase degrader, selectively reduces levels of ATR and phospho-ATR while not impacting the related kinases ATM and DNA-PKcs [1]. |
In vitro | Abd110 (compound 42i; 0.5-2 μM; 24 h) selectively degrades ATR by relying on the E3 ubiquitin ligase component cereblon, while not affecting the related kinases ATM and DNA-PKcs [1]. In a cell viability assay using the MIA PaCa-2 cell line at concentrations of 0.5 μM, 1 μM, and 2 μM for 24 hours, Abd110 resulted in decreased levels of ATR and p-ATR without impacting other checkpoint kinases. |
Molecular Weight | 790.89 |
Formula | C41H42N8O7S |
Cas No. | 3021581-79-0 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.